Salinomycin treatment reduces metastatic tumor burden by hampering cancer cell migrationReport as inadecuate




Salinomycin treatment reduces metastatic tumor burden by hampering cancer cell migration - Download this document for free, or read online. Document in PDF available to download.

Molecular Cancer

, 13:16

First Online: 27 January 2014Received: 19 September 2013Accepted: 24 January 2014DOI: 10.1186-1476-4598-13-16

Cite this article as: Kopp, F., Hermawan, A., Oak, P.S. et al. Mol Cancer 2014 13: 16. doi:10.1186-1476-4598-13-16

Abstract

BackgroundTumor spreading is the major threat for cancer patients. The recently published anti-cancer drug salinomycin raised hope for an improved treatment by targeting therapy-refractory cancer stem cells. However, an unambiguous role of salinomycin against cancer cell migration and metastasis formation remains elusive.

FindingsWe report that salinomycin effectively inhibits cancer cell migration in a variety of cancer types as determined by Boyden chamber assays. Additionally, cells were treated with doxorubicin at a concentration causing a comparable low cytotoxicity, emphasizing the anti-migratory potential of salinomycin. Moreover, single-cell tracking by time-lapse microscopy demonstrated a remarkable effect of salinomycin on breast cancer cell motility. Ultimately, salinomycin treatment significantly reduced the metastatic tumor burden in a syngenic mouse tumor model.

ConclusionsOur findings clearly show that salinomycin can strongly inhibit cancer cell migration independent of the induction of cell death. We furthermore demonstrate for the first time that salinomycin treatment reduces metastasis formation in vivo, strengthening its role as promising anti-cancer therapeutic.

KeywordsSalinomycin Cancer Migration Cell motility Metastasis AbbreviationsCSCCancer stem cells.

Electronic supplementary materialThe online version of this article doi:10.1186-1476-4598-13-16 contains supplementary material, which is available to authorized users.

Download fulltext PDF



Author: Florian Kopp - Adam Hermawan - Prajakta Shirish Oak - Annika Herrmann - Ernst Wagner - Andreas Roidl

Source: https://link.springer.com/







Related documents